HemCon Medical Technologies, Inc Report issue

For profit Phase 2
Founded: Portland OR United States (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2010
NCT00968487
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

blood plasma (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Liver Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1